Share this article
Share this article
LEXINGTON, Ky., Feb. 1, 2021 /PRNewswire/ Neogen Corporation (NASDAQ: NEOG) announced today that it has relaunched its popular ThyroKare
™ (levothyroxine sodium tablets), USP, which are approved by the FDA for replacement therapy for diminished thyroid function in dogs.
Hypothyroidism is the most common endocrine disorder in dogs, affecting more than 5% of its population. While hypothyroidism can t be cured, daily replacement therapy with products such as ThyroKare allows for dogs to live full, normal lives following diagnosis. We are very pleased to receive this FDA approval for ThyroKare, and return to the marketplace with this important product that complements our expanding suite of companion animal diagnostic and treatment offerings, said John Adent, Neogen s CEO and president.